Answer
Breastfeeding should be discontinued throughout cabozantinib treatment and for at least 4 months after completing therapy because of potential harm to the infant.
Sources for this answer
- COMETRIQ 20 & 80 mg hard capsulesIpsen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 15Document updated
Sources checked